MARKET

CKPT

CKPT

Checkpoint Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.330
-0.100
-4.12%
After Hours: 2.200 -0.13 -5.58% 18:07 10/28 EDT
OPEN
2.360
PREV CLOSE
2.430
HIGH
2.360
LOW
2.250
VOLUME
303.22K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.050
MARKET CAP
168.46M
P/E (TTM)
-4.5103
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
What Kind Of Shareholders Hold The Majority In Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shares?
Every investor in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) should be aware of the most powerful shareholder groups...
Simply Wall St. · 3d ago
How Much Did Checkpoint Therapeutics'(NASDAQ:CKPT) Shareholders Earn From Share Price Movements Over The Last Three Years?
It is a pleasure to report that the Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) is up 57% in the last quarter. But...
Simply Wall St. · 09/19 15:01
Cassava Sciences, Evogene leads the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology amond major losers
Gainers: Cassava Sciences (SAVA) +41%, Evogene (EVGN) +26%, AlloVir (ALVR) +15%, Abeona Therapeutics (ABEO) +15%, Sonoma Pharmaceuticals (SNOA) +14%.Losers: Ayala Pharmaceuticals (AYLA) -12%, Clovis Oncology (CLVS) -10%, Checkpoint Therapeutics (CKPT) -9%, Seres Therapeutics (MCRB) -8%, Innate Pharma (IPHA) -5%.
Seekingalpha · 09/18 14:56
Mid-Morning Market Update: Markets Mixed; US Consumer Sentiment Rises In September
Following the market opening Friday, the Dow traded down 0.18% to 27850.97 while the NASDAQ rose 0.18% to 10,930.12. The S&P also fell, dropping 0.06% to 3,355.02.
Benzinga · 09/18 14:16
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
Checkpoint Therapeutics announces $20M bought deal offering
Checkpoint Therapeutics (CKPT) enters into an underwriting agreement with H.C. Wainwright & Co to purchase 7,142,857 shares at a price of $2.80 per share, less underwriting discounts and commissions. Offering expected
Seekingalpha · 09/17 21:37
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter
GlobeNewswire · 09/17 21:27
Sorrento Therapeutics, Phio Pharmaceuticals leads healthcare gainers, Strongbridge Biopharma, Nano-X Imaging among major losers
Gainers: Sorrento Therapeutics (SRNE) +24%, Entera Bio (ENTX) +23%,  Vaccinex (VCNX) +17%, Vaxart (VXRT) +15%, Phio Pharmaceuticals (PHIO) +14%Losers: Strongbridge Biopharma (SBBP) -19%, Nano-X Imaging (NNOX) -16%, Checkpoint Therapeutics (CKPT) -14%, NuCana (NCNA) -11%, Inovio Pharmaceuticals (INO) -11%.
Seekingalpha · 09/17 15:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CKPT. Analyze the recent business situations of Checkpoint Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CKPT stock price target is 15.00 with a high estimate of 20.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 58
Institutional Holdings: 7.17M
% Owned: 9.92%
Shares Outstanding: 72.30M
TypeInstitutionsShares
Increased
20
1.38M
New
15
78.89K
Decreased
6
133.12K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director
Michael Weiss
President/Chief Executive Officer/Director
James Oliviero
Chief Financial Officer/Vice President - Finance/Secretary
William Gray
Director
Lindsay Rosenwald
Independent Director
Christian Bechon
Independent Director
Scott Boilen
Independent Director
Neil Herskowitz
Independent Director
Barry Salzman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CKPT
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Checkpoint Therapeutics Inc stock information, including NASDAQ:CKPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CKPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CKPT stock methods without spending real money on the virtual paper trading platform.